Lv21
130 积分 2024-07-06 加入
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
20天前
已完结
First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN Study
20天前
已完结
First-line lorlatinib versus crizotinib in Asian patients with advanced ALK-positive NSCLC: 5-year outcomes from the CROWN study
1个月前
已完结
Erratum to ‘Diabetic Ketoacidosis During Lorlatinib Treatment: Case Report’ [Journal of Thoracic Oncology Volume 20, Issue 5 (2025) 676-679]
1个月前
已完结
Lung adenocarcinoma with EGFR 19Del and an ALK rearrangement benefits from alectinib instead of an EGFR-TKI: A case report
1个月前
已完结
Neoadjuvant target therapy with ensartinib in lung adenocarcinoma with EML4-ALK fusion variant: a case report and literature review
1个月前
已完结
Therapeutic strategies to overcome ALK-fusion and BRAF-mutation as acquired resistance mechanism in EGFR-mutated non-small cell lung cancer: two case reports
1个月前
已完结
Ensartinib for EML4-ALK-positive lung adenocarcinoma with comorbid mutations in TP53, EGFR, and ERBB2: a case report
1个月前
已完结
First-line treatment for advanced NSCLC in older patients and those with poor performance status
1个月前
已完结
Brain metastases and mortality in patients with ALK + metastatic non-small cell lung cancer treated with second-generation ALK tyrosine kinase inhibitors as first-line targeted therapies: An observational cohort study
2个月前
已完结
皖公网安备34019202002308
